niclosamide has been researched along with Infections, Coronavirus in 5 studies
Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48)
niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Niclosamide (NIC) has demonstrated promising in vitro antiviral efficacy against SARS-CoV-2, the causative agent of the COVID-19 pandemic." | 5.62 | Development and evaluation of inhalable composite niclosamide-lysozyme particles: A broad-spectrum, patient-adaptable treatment for coronavirus infections and sequalae. ( Brunaugh, AD; Ding, L; Seo, H; Seo, SH; Smyth, HDC; Warnken, Z, 2021) |
| "The recent outbreak of coronavirus disease 2019 (COVID-19) highlights an urgent need for therapeutics." | 2.66 | Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential. ( Li, H; Shi, PY; Xu, J; Zhou, J, 2020) |
| "Niclosamide (NIC) has demonstrated promising in vitro antiviral efficacy against SARS-CoV-2, the causative agent of the COVID-19 pandemic." | 1.62 | Development and evaluation of inhalable composite niclosamide-lysozyme particles: A broad-spectrum, patient-adaptable treatment for coronavirus infections and sequalae. ( Brunaugh, AD; Ding, L; Seo, H; Seo, SH; Smyth, HDC; Warnken, Z, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 5 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jeon, S | 1 |
| Ko, M | 1 |
| Lee, J | 1 |
| Choi, I | 1 |
| Byun, SY | 1 |
| Park, S | 1 |
| Shum, D | 1 |
| Kim, S | 1 |
| Wang, Y | 1 |
| Huang, H | 1 |
| Li, D | 1 |
| Zhao, C | 1 |
| Li, S | 1 |
| Qin, P | 1 |
| Li, Y | 2 |
| Yang, X | 1 |
| Du, W | 1 |
| Li, W | 1 |
| Xu, J | 1 |
| Shi, PY | 1 |
| Li, H | 1 |
| Zhou, J | 1 |
| Gupta, SP | 1 |
| Brunaugh, AD | 1 |
| Seo, H | 1 |
| Warnken, Z | 1 |
| Ding, L | 1 |
| Seo, SH | 1 |
| Smyth, HDC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of Silver Nanoparticles as an Oropharyngeal Product (Mouthwash) and Nasal Hygiene, by Health Personnel Working at the Tijuana General Hospital Exposed to Patients Diagnosed With Atypical Pneumonia Caused by SARS-CoV-2[NCT04894409] | 231 participants (Actual) | Interventional | 2020-04-24 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for niclosamide and Infections, Coronavirus
| Article | Year |
|---|---|
Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential.
Topics: Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug R | 2020 |
Progress in Studies on Structural and Remedial Aspects of Newly Born Coronavirus, SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme 2; Antiviral Agents; Betacoronavirus | 2020 |
3 other studies available for niclosamide and Infections, Coronavirus
| Article | Year |
|---|---|
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
Topics: Animals; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiop | 2020 |
Identification of niclosamide as a novel antiviral agent against porcine epidemic diarrhea virus infection by targeting viral internalization.
Topics: Animals; Antiviral Agents; Chlorocebus aethiops; Coronavirus Infections; Niclosamide; Porcine epidem | 2023 |
Development and evaluation of inhalable composite niclosamide-lysozyme particles: A broad-spectrum, patient-adaptable treatment for coronavirus infections and sequalae.
Topics: Administration, Inhalation; Animals; Antiviral Agents; Cell Line; Coronavirus Infections; COVID-19 D | 2021 |